0

524663

BIBCL

img img img img
No Data Available

BHARAT IMMUNOLOGICALS & BIOLOG Share Price Update

As of the latest trading session, BHARAT IMMUNOLOGICALS & BIOLOG is trading at ₹17.24, down by ₹-0.46 or -2.59% from its previous close. The stock has moved between ₹17.00 and ₹17.66 today. Over the past year, the stock has delivered a return of -24.74%. In the last month, it has returned 20.98%.

Investment Returns

Over 1 Month 20.98% Over 3 Months -3.95% Over 6 Months -16.27% Over 1 Year -24.74%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BHARAT IMMUNOLOGICALS & BIOLOG fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 74.40
  • P/E Ratio (TTM) -4.12
  • Beta 0.74
  • Book Value / share -7.53
  • Return on equity 0.00%
  • EPS (TTM) 0.00
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -4.92
info icon alternate text

BHARAT IMMUNOLOGICALS & BIOLOG Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars SEP 2023 (Values in Cr)
Revenue 0.00
Operating Expense 6.81
Net Profit -4.92
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -1.14
EBITDA -4.53
Effective Tax Rate (%) 26.01
Particulars JUN 2023 (Values in Cr)
Revenue 0.00
Operating Expense 6.06
Net Profit -4.59
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -1.06
EBITDA -4.22
Effective Tax Rate (%) 23.11
Particulars MAR 2023 (Values in Cr)
Revenue 7.65
Operating Expense 13.82
Net Profit -3.88
Net Profit Margin (%) -50.71
Earnings Per Share (EPS) -0.90
EBITDA -3.53
Effective Tax Rate (%) 31.69
Particulars DEC 2022 (Values in Cr)
Revenue 0.00
Operating Expense 6.43
Net Profit -4.68
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -1.08
EBITDA -4.62
Effective Tax Rate (%) 26.06
Particulars SEP 2022 (Values in Cr)
Revenue 26.48
Operating Expense 30.75
Net Profit -3.08
Net Profit Margin (%) -11.63
Earnings Per Share (EPS) -0.71
EBITDA -2.17
Effective Tax Rate (%) 22.22
Particulars MAR 2023 (Values in Cr)
Revenue 44.61
Operating Expense 67.94
Net Profit -16.64
Net Profit Margin (%) -37.30
Earnings Per Share (EPS) -3.85
EBITDA -15.02
Effective Tax Rate (%) 25.28
Particulars MAR 2022 (Values in Cr)
Revenue 78.39
Operating Expense 89.18
Net Profit -8.75
Net Profit Margin (%) -11.16
Earnings Per Share (EPS) -2.03
EBITDA -3.88
Effective Tax Rate (%) 9.59
Particulars MAR 2021 (Values in Cr)
Revenue 85.33
Operating Expense 111.22
Net Profit -18.11
Net Profit Margin (%) -21.22
Earnings Per Share (EPS) 1.10
EBITDA -19.19
Effective Tax Rate (%) 25.19
Particulars MAR 2020 (Values in Cr)
Revenue 66.84
Operating Expense 82.22
Net Profit -10.21
Net Profit Margin (%) -15.27
Earnings Per Share (EPS) -2.36
EBITDA -9.21
Effective Tax Rate (%) 28.09
Particulars MAR 2019 (Values in Cr)
Revenue 83.65
Operating Expense 95.24
Net Profit -5.79
Net Profit Margin (%) -6.92
Earnings Per Share (EPS) -1.57
EBITDA -5.09
Effective Tax Rate (%) 21.43
Particulars MAR 2023 (Values in Cr)
Book Value / Share -5.43
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -35.10
Particulars MAR 2022 (Values in Cr)
Book Value / Share -1.48
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -4.94
Particulars MAR 2021 (Values in Cr)
Book Value / Share 0.55
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.33
EBITDA Margin -22.48
Particulars MAR 2020 (Values in Cr)
Book Value / Share 4.74
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.69
EBITDA Margin -13.79
Particulars MAR 2019 (Values in Cr)
Book Value / Share 7.10
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.47
EBITDA Margin -6.10
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.73
Total Assets 185.66
Total Liabilities 185.66
Total Equity 87.79
Share Outstanding 4
Price to Book Ratio -4.09
Return on Assets (%) -9.18
Return on Capital (%) -10.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 13.00
Total Assets 212.72
Total Liabilities 212.72
Total Equity 105.35
Share Outstanding 4
Price to Book Ratio -18.99
Return on Assets (%) -4.11
Return on Capital (%) -4.78
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.53
Total Assets 103.98
Total Liabilities 103.98
Total Equity 34.04
Share Outstanding 4
Price to Book Ratio 82.73
Return on Assets (%) -17.41
Return on Capital (%) -29.53
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 12.09
Total Assets 126.82
Total Liabilities 126.82
Total Equity 20.47
Share Outstanding 4
Price to Book Ratio 1.23
Return on Assets (%) -8.05
Return on Capital (%) -43.43
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 7.93
Total Assets 124.96
Total Liabilities 124.96
Total Equity 30.67
Share Outstanding 4
Price to Book Ratio 1.08
Return on Assets (%) -4.63
Return on Capital (%) -9.21
Particulars MAR 2023 (Values in Cr)
Net Income -22.85
Cash from Operations 10.88
Cash from Investing 0.46
Cash from Financing -14.70
Net change in Cash -3.35
Free Cash Flow 10.88
Particulars MAR 2022 (Values in Cr)
Net Income -9.68
Cash from Operations -42.11
Cash from Investing 0.53
Cash from Financing 45.00
Net change in Cash 3.41
Free Cash Flow -42.11
Particulars MAR 2021 (Values in Cr)
Net Income -24.20
Cash from Operations 11.77
Cash from Investing 0.66
Cash from Financing -12.20
Net change in Cash 0.24
Free Cash Flow 11.77
Particulars MAR 2020 (Values in Cr)
Net Income -14.20
Cash from Operations 34.07
Cash from Investing 0.91
Cash from Financing -34.41
Net change in Cash 0.57
Free Cash Flow 34.07
Particulars MAR 2019 (Values in Cr)
Net Income -7.37
Cash from Operations -32.09
Cash from Investing 0.69
Cash from Financing 30.70
Net change in Cash -0.69
Free Cash Flow -32.07
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.80 13.77 1.65 243.69 23.12 40.44
BLISS GVS PHARMA LTD 276.25 26.41 2.58 2922.42 105.05 280.20
CIPLA LTD 1309.90 22.25 3.21 105811.45 1165.55 1672.20
FERMENTA BIOTECH LIMITED 311.40 10.36 2.34 916.48 252.15 399.00
GLAXOSMITHKLINE PHARMA LT 2335.60 39.34 23.16 39566.47 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.80 30.58 4.43 243.69 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 570.45 28.52 4.82 1649.21 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8217.20 98.75 25.71 20543.00 7630.00 10653.05
BLISS GVS PHARMA LTD 276.25 37.64 2.64 2922.42 105.05 280.20

BHARAT IMMUNOLOGICALS & BIOLOG shareholding pattern

Holding
40.74%
59.25%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

BHARAT IMMUNOLOGICALS & BIOLOG Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
17.24 -2.59 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 17.50
  • 26 Days 17.30
  • 10 Days 17.50
  • 50 Days 17.40
  • 12 Days 17.40
  • 100 Days 18.20
  • 20 Days 17.30
  • 200 Days 19.70
17.73 PIVOT
First Support 17.51 First Resistance 17.91 Second Support 17.33 Second Resistance 18.13 Third Support 17.11 Third Resistance 18.31
RSI 49.60 ADX 15.50 MACD 0.16 Williams % R -66.67 Commodity Channel Index (CCI) 5.83
Date 2026-04-30 Week 18924.00 Same Day 13062.00 Month 25677.00
1 Year 0.75 3 Year 0.85
Over 1 Month
20.98% down
Over 1 Year
-24.74% down
Over 3 Months
-3.95% down
Over 3 Years
-10.25% down
Over 6 Months
-16.27% down
Over 5 Years
-17.91% down

BHARAT IMMUNOLOGICALS & BIOLOG Corporate Actions

Top Gainers

Top Losers

BHARAT IMMUNOLOGICALS & BIOLOG Share Price

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology. BIBCOL was incorporated in 1989. The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets.

The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh. BIBCL installed a plant of 100 mln units. Commercial production of the OPV started from Jan'96.

The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme. It has set up an R&D unit for the development of hepatitis B vaccine through transfer of technology from the US.

In year 2006, the facility was up graded to meet the WHO cGMP & revised schedule M of Drugs & Cosmetics Act. In 2016, BIBCOL switched over to bOPV from tOPV . To add in product line, company diversified into Plasma derived medicines, and Oral Cholera Vaccine.

Parent organization Government of India
NSE symbol [-]
Founded 1989
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Bharat Immunological & Biological Corporation Ltd?

Answer Field

Bharat Immunological & Biological Corporation Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 17.24 as on Apr 30 2026 03:30 PM.

What is the Market Cap of Bharat Immunological & Biological Corporation Ltd Share?

Answer Field

The market cap of Bharat Immunological & Biological Corporation Ltd for NSE ₹ 0.00 & for BSE ₹ 74.40 as on Apr 30 2026 03:30 PM.

What is the 52 Week High and Low of Bharat Immunological & Biological Corporation Ltd?

Answer Field

The 52 Week High and Low of Bharat Immunological & Biological Corporation Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 28.80 and ₹ 14.10.

What is 1 year return for Bharat Immunological & Biological Corporation Ltd?

Answer Field

The 1 year returns on the stock has been -24.74%.

What is the P/E Ratio of Bharat Immunological & Biological Corporation Ltd Share?

Answer Field

As on Apr 30 2026 03:30 PM the price-to-earnings (PE) ratio for Bharat Immunological & Biological Corporation Ltd share is -4.12.

What is the PB ratio of Bharat Immunological & Biological Corporation Ltd Share?

Answer Field

As on Apr 30 2026 03:30 PM, the price-to-book (PB) ratio for Bharat Immunological & Biological Corporation Ltd share is -7.53.

How to Buy Bharat Immunological & Biological Corporation Ltd Share?

Answer Field

You can trade in Bharat Immunological & Biological Corporation Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Bharat Immunological & Biological Corporation Ltd Share on Bajaj Broking App?

Answer Field

To buy Bharat Immunological & Biological Corporation Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Bharat Immunological & Biological Corporation Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|